nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—Imatinib—hematologic cancer	0.222	1	CrCtD
Nilotinib—Protein Kinase Inhibitors—Ruxolitinib—hematologic cancer	0.22	1	CiPCiCtD
Nilotinib—Ponatinib—Imatinib—hematologic cancer	0.126	1	CrCrCtD
Nilotinib—ABL2—hematologic cancer	0.0189	0.12	CbGaD
Nilotinib—LCK—hematologic cancer	0.018	0.115	CbGaD
Nilotinib—MAPK8—hematologic cancer	0.0166	0.106	CbGaD
Nilotinib—FGR—hematologic cancer	0.0161	0.102	CbGaD
Nilotinib—MAPK14—hematologic cancer	0.0161	0.102	CbGaD
Nilotinib—CSF1R—hematologic cancer	0.0109	0.069	CbGaD
Nilotinib—PDGFRB—hematologic cancer	0.00947	0.0602	CbGaD
Nilotinib—PDGFRA—hematologic cancer	0.00923	0.0586	CbGaD
Nilotinib—BRAF—hematologic cancer	0.00844	0.0536	CbGaD
Nilotinib—ABL1—hematologic cancer	0.00844	0.0536	CbGaD
Nilotinib—EPHB3—Dasatinib—hematologic cancer	0.00683	0.0422	CbGbCtD
Nilotinib—EPHB2—Dasatinib—hematologic cancer	0.00683	0.0422	CbGbCtD
Nilotinib—HCK—Dasatinib—hematologic cancer	0.00683	0.0422	CbGbCtD
Nilotinib—KIT—hematologic cancer	0.00678	0.043	CbGaD
Nilotinib—UGT1A1—hematologic cancer	0.00668	0.0424	CbGaD
Nilotinib—CA9—hematologic cancer	0.00651	0.0413	CbGaD
Nilotinib—CA3—Imatinib—hematologic cancer	0.00565	0.0349	CbGbCtD
Nilotinib—EPHA3—Dasatinib—hematologic cancer	0.00543	0.0335	CbGbCtD
Nilotinib—FRK—Dasatinib—hematologic cancer	0.00543	0.0335	CbGbCtD
Nilotinib—EPHA4—Dasatinib—hematologic cancer	0.00543	0.0335	CbGbCtD
Nilotinib—EPHB4—Dasatinib—hematologic cancer	0.00543	0.0335	CbGbCtD
Nilotinib—MAPK14—Dasatinib—hematologic cancer	0.00543	0.0335	CbGbCtD
Nilotinib—EPHA2—Dasatinib—hematologic cancer	0.00454	0.028	CbGbCtD
Nilotinib—EPHA8—Dasatinib—hematologic cancer	0.00454	0.028	CbGbCtD
Nilotinib—FGR—Dasatinib—hematologic cancer	0.00392	0.0242	CbGbCtD
Nilotinib—CSF1R—Imatinib—hematologic cancer	0.00388	0.024	CbGbCtD
Nilotinib—PDGFRA—Imatinib—hematologic cancer	0.00388	0.024	CbGbCtD
Nilotinib—ABL2—Imatinib—hematologic cancer	0.00388	0.024	CbGbCtD
Nilotinib—KIT—Imatinib—hematologic cancer	0.00388	0.024	CbGbCtD
Nilotinib—ABCG2—hematologic cancer	0.00375	0.0238	CbGaD
Nilotinib—LCK—Imatinib—hematologic cancer	0.00353	0.0218	CbGbCtD
Nilotinib—PDGFRB—Imatinib—hematologic cancer	0.00353	0.0218	CbGbCtD
Nilotinib—LYN—Dasatinib—hematologic cancer	0.00347	0.0214	CbGbCtD
Nilotinib—BLK—Dasatinib—hematologic cancer	0.00347	0.0214	CbGbCtD
Nilotinib—EPHB6—Dasatinib—hematologic cancer	0.00347	0.0214	CbGbCtD
Nilotinib—CSF1R—Dasatinib—hematologic cancer	0.00312	0.0193	CbGbCtD
Nilotinib—KIT—Dasatinib—hematologic cancer	0.00312	0.0193	CbGbCtD
Nilotinib—PDGFRA—Dasatinib—hematologic cancer	0.00312	0.0193	CbGbCtD
Nilotinib—ABL2—Dasatinib—hematologic cancer	0.00312	0.0193	CbGbCtD
Nilotinib—MAP2K5—Dasatinib—hematologic cancer	0.00284	0.0175	CbGbCtD
Nilotinib—PDGFRB—Dasatinib—hematologic cancer	0.00284	0.0175	CbGbCtD
Nilotinib—LCK—Dasatinib—hematologic cancer	0.00284	0.0175	CbGbCtD
Nilotinib—ABL1—Imatinib—hematologic cancer	0.00281	0.0173	CbGbCtD
Nilotinib—CA14—Imatinib—hematologic cancer	0.00235	0.0145	CbGbCtD
Nilotinib—ABL1—Dasatinib—hematologic cancer	0.00225	0.0139	CbGbCtD
Nilotinib—CA6—Imatinib—hematologic cancer	0.00223	0.0138	CbGbCtD
Nilotinib—CA7—Imatinib—hematologic cancer	0.00194	0.012	CbGbCtD
Nilotinib—CA9—Imatinib—hematologic cancer	0.00167	0.0103	CbGbCtD
Nilotinib—CA12—Imatinib—hematologic cancer	0.00167	0.0103	CbGbCtD
Nilotinib—ABCB1—hematologic cancer	0.00156	0.00992	CbGaD
Nilotinib—CA1—Imatinib—hematologic cancer	0.00156	0.00963	CbGbCtD
Nilotinib—ABCG2—Clofarabine—hematologic cancer	0.00143	0.00881	CbGbCtD
Nilotinib—CA2—Imatinib—hematologic cancer	0.00135	0.00833	CbGbCtD
Nilotinib—ABCG2—Daunorubicin—hematologic cancer	0.000837	0.00517	CbGbCtD
Nilotinib—CYP2B6—Thiotepa—hematologic cancer	0.000832	0.00514	CbGbCtD
Nilotinib—UGT1A1—Irinotecan—hematologic cancer	0.000728	0.00449	CbGbCtD
Nilotinib—ABCG2—Teniposide—hematologic cancer	0.000727	0.00449	CbGbCtD
Nilotinib—ABCG2—Cladribine—hematologic cancer	0.000697	0.0043	CbGbCtD
Nilotinib—ABCG2—Imatinib—hematologic cancer	0.000641	0.00396	CbGbCtD
Nilotinib—UGT1A1—Etoposide—hematologic cancer	0.000583	0.0036	CbGbCtD
Nilotinib—CYP2C9—Bexarotene—hematologic cancer	0.00053	0.00327	CbGbCtD
Nilotinib—ABCG2—Dasatinib—hematologic cancer	0.000515	0.00318	CbGbCtD
Nilotinib—ABCB1—Lenalidomide—hematologic cancer	0.000515	0.00318	CbGbCtD
Nilotinib—ABCG2—Mitoxantrone—hematologic cancer	0.000508	0.00314	CbGbCtD
Nilotinib—CYP2B6—Ifosfamide—hematologic cancer	0.000472	0.00291	CbGbCtD
Nilotinib—CYP2C8—Bortezomib—hematologic cancer	0.000466	0.00288	CbGbCtD
Nilotinib—CYP2D6—Lomustine—hematologic cancer	0.000451	0.00278	CbGbCtD
Nilotinib—CYP2C9—Idarubicin—hematologic cancer	0.000439	0.00271	CbGbCtD
Nilotinib—CYP2D6—Idarubicin—hematologic cancer	0.000402	0.00248	CbGbCtD
Nilotinib—ABCG2—Irinotecan—hematologic cancer	0.0004	0.00247	CbGbCtD
Nilotinib—CYP2C8—Ifosfamide—hematologic cancer	0.000357	0.00221	CbGbCtD
Nilotinib—ABCG2—Vincristine—hematologic cancer	0.00035	0.00216	CbGbCtD
Nilotinib—CYP2D6—Hydroxyurea—hematologic cancer	0.000342	0.00211	CbGbCtD
Nilotinib—FRK—hematopoietic system—hematologic cancer	0.000332	0.0188	CbGeAlD
Nilotinib—ABCG2—Cisplatin—hematologic cancer	0.000326	0.00202	CbGbCtD
Nilotinib—CYP2C9—Bortezomib—hematologic cancer	0.000325	0.00201	CbGbCtD
Nilotinib—ABCG2—Etoposide—hematologic cancer	0.000321	0.00198	CbGbCtD
Nilotinib—BLK—hematopoietic system—hematologic cancer	0.00032	0.0181	CbGeAlD
Nilotinib—EPHB2—hematopoietic system—hematologic cancer	0.000316	0.0179	CbGeAlD
Nilotinib—CYP3A4—Bexarotene—hematologic cancer	0.000308	0.0019	CbGbCtD
Nilotinib—ABCB1—Daunorubicin—hematologic cancer	0.000302	0.00186	CbGbCtD
Nilotinib—CYP2D6—Bortezomib—hematologic cancer	0.000297	0.00184	CbGbCtD
Nilotinib—ABCB1—Alitretinoin—hematologic cancer	0.000296	0.00183	CbGbCtD
Nilotinib—CYP3A4—Busulfan—hematologic cancer	0.000287	0.00177	CbGbCtD
Nilotinib—CYP3A4—Lomustine—hematologic cancer	0.000287	0.00177	CbGbCtD
Nilotinib—CYP2C9—Thalidomide—hematologic cancer	0.000283	0.00175	CbGbCtD
Nilotinib—CYP2B6—Irinotecan—hematologic cancer	0.000282	0.00174	CbGbCtD
Nilotinib—CYP2C9—Teniposide—hematologic cancer	0.00027	0.00167	CbGbCtD
Nilotinib—ABCG2—Dexamethasone—hematologic cancer	0.000264	0.00163	CbGbCtD
Nilotinib—CYP3A4—Thiotepa—hematologic cancer	0.000256	0.00158	CbGbCtD
Nilotinib—MAPK8—hematopoietic system—hematologic cancer	0.000253	0.0143	CbGeAlD
Nilotinib—FRK—gonad—hematologic cancer	0.000252	0.0143	CbGeAlD
Nilotinib—CYP2C9—Ifosfamide—hematologic cancer	0.000249	0.00154	CbGbCtD
Nilotinib—Ponatinib—BCR—hematologic cancer	0.000245	0.164	CrCbGaD
Nilotinib—CYP2C9—Imatinib—hematologic cancer	0.000238	0.00147	CbGbCtD
Nilotinib—LYN—hematopoietic system—hematologic cancer	0.000233	0.0132	CbGeAlD
Nilotinib—ABCB1—Imatinib—hematologic cancer	0.000231	0.00143	CbGbCtD
Nilotinib—MAP4K1—hematopoietic system—hematologic cancer	0.00023	0.013	CbGeAlD
Nilotinib—CYP2B6—Cisplatin—hematologic cancer	0.00023	0.00142	CbGbCtD
Nilotinib—TIE1—hematopoietic system—hematologic cancer	0.000219	0.0124	CbGeAlD
Nilotinib—ABCG2—Doxorubicin—hematologic cancer	0.000219	0.00135	CbGbCtD
Nilotinib—CYP2D6—Imatinib—hematologic cancer	0.000218	0.00134	CbGbCtD
Nilotinib—CDC42BPB—gonad—hematologic cancer	0.000213	0.012	CbGeAlD
Nilotinib—BLK—blood—hematologic cancer	0.000212	0.012	CbGeAlD
Nilotinib—ABCG2—Methotrexate—hematologic cancer	0.000212	0.00131	CbGbCtD
Nilotinib—ABCB1—Vinorelbine—hematologic cancer	0.000208	0.00129	CbGbCtD
Nilotinib—CYP3A4—Methoxsalen—hematologic cancer	0.000199	0.00123	CbGbCtD
Nilotinib—CYP2D6—Vinorelbine—hematologic cancer	0.000196	0.00121	CbGbCtD
Nilotinib—MAPK8—gonad—hematologic cancer	0.000192	0.0109	CbGeAlD
Nilotinib—EPHA6—gonad—hematologic cancer	0.000192	0.0109	CbGeAlD
Nilotinib—HCK—hematopoietic system—hematologic cancer	0.000192	0.0108	CbGeAlD
Nilotinib—CYP3A4—Bortezomib—hematologic cancer	0.000189	0.00117	CbGbCtD
Nilotinib—ABCB1—Dasatinib—hematologic cancer	0.000186	0.00115	CbGbCtD
Nilotinib—CYP2B6—Dexamethasone—hematologic cancer	0.000185	0.00115	CbGbCtD
Nilotinib—ABCB1—Mitoxantrone—hematologic cancer	0.000183	0.00113	CbGbCtD
Nilotinib—FRK—testis—hematologic cancer	0.000182	0.0103	CbGeAlD
Nilotinib—CYP3A4—Daunorubicin—hematologic cancer	0.000181	0.00112	CbGbCtD
Nilotinib—CYP2C8—Etoposide—hematologic cancer	0.000171	0.00105	CbGbCtD
Nilotinib—MAPK8—blood—hematologic cancer	0.000168	0.00948	CbGeAlD
Nilotinib—EPHA8—testis—hematologic cancer	0.000166	0.0094	CbGeAlD
Nilotinib—ABCB1—Betamethasone—hematologic cancer	0.000163	0.00101	CbGbCtD
Nilotinib—CDC42BPB—lung—hematologic cancer	0.000162	0.00919	CbGeAlD
Nilotinib—MAPK8—bone marrow—hematologic cancer	0.000162	0.00917	CbGeAlD
Nilotinib—ABCB1—Gemcitabine—hematologic cancer	0.000162	0.001	CbGbCtD
Nilotinib—ABCB1—Prednisolone—hematologic cancer	0.000161	0.000996	CbGbCtD
Nilotinib—MAPK14—hematopoietic system—hematologic cancer	0.000161	0.00908	CbGeAlD
Nilotinib—FGR—hematopoietic system—hematologic cancer	0.00016	0.00905	CbGeAlD
Nilotinib—CYP3A4—Cytarabine—hematologic cancer	0.000159	0.000985	CbGbCtD
Nilotinib—Ponatinib—FLT3—hematologic cancer	0.000158	0.106	CrCbGaD
Nilotinib—CYP3A4—Teniposide—hematologic cancer	0.000157	0.00097	CbGbCtD
Nilotinib—LYN—blood—hematologic cancer	0.000155	0.00875	CbGeAlD
Nilotinib—MAPK11—testis—hematologic cancer	0.000155	0.00874	CbGeAlD
Nilotinib—EPHA3—lung—hematologic cancer	0.000154	0.00871	CbGeAlD
Nilotinib—CYP2B6—Doxorubicin—hematologic cancer	0.000154	0.00095	CbGbCtD
Nilotinib—CDC42BPB—testis—hematologic cancer	0.000153	0.00867	CbGeAlD
Nilotinib—MAP4K1—blood—hematologic cancer	0.000152	0.00861	CbGeAlD
Nilotinib—EPHB4—hematopoietic system—hematologic cancer	0.000152	0.00861	CbGeAlD
Nilotinib—ABCB1—Prednisone—hematologic cancer	0.000152	0.00094	CbGbCtD
Nilotinib—EPHA2—hematopoietic system—hematologic cancer	0.000149	0.00845	CbGeAlD
Nilotinib—MAP4K1—bone marrow—hematologic cancer	0.000147	0.00833	CbGeAlD
Nilotinib—MAPK8—lung—hematologic cancer	0.000147	0.00831	CbGeAlD
Nilotinib—TEK—hematopoietic system—hematologic cancer	0.000146	0.00824	CbGeAlD
Nilotinib—EPHA3—testis—hematologic cancer	0.000145	0.00822	CbGeAlD
Nilotinib—CYP3A4—Ifosfamide—hematologic cancer	0.000145	0.000895	CbGbCtD
Nilotinib—ABCB1—Irinotecan—hematologic cancer	0.000144	0.000891	CbGbCtD
Nilotinib—CYP2C8—Dexamethasone—hematologic cancer	0.00014	0.000867	CbGbCtD
Nilotinib—BRAF—blood—hematologic cancer	0.000139	0.00788	CbGeAlD
Nilotinib—MAPK8—testis—hematologic cancer	0.000139	0.00784	CbGeAlD
Nilotinib—EPHA6—testis—hematologic cancer	0.000139	0.00784	CbGeAlD
Nilotinib—CYP3A4—Imatinib—hematologic cancer	0.000138	0.000855	CbGbCtD
Nilotinib—BRAF—bone marrow—hematologic cancer	0.000135	0.00762	CbGeAlD
Nilotinib—Ponatinib—LCK—hematologic cancer	0.000134	0.0901	CrCbGaD
Nilotinib—MAP4K1—lung—hematologic cancer	0.000134	0.00755	CbGeAlD
Nilotinib—EPHA4—gonad—hematologic cancer	0.000132	0.00749	CbGeAlD
Nilotinib—PDGFRA—hematopoietic system—hematologic cancer	0.000132	0.00747	CbGeAlD
Nilotinib—CYP3A4—Ruxolitinib—hematologic cancer	0.00013	0.000805	CbGbCtD
Nilotinib—ABCB1—Vinblastine—hematologic cancer	0.000128	0.000793	CbGbCtD
Nilotinib—TIE1—lung—hematologic cancer	0.000127	0.0072	CbGeAlD
Nilotinib—BLK—lymph node—hematologic cancer	0.000127	0.00719	CbGeAlD
Nilotinib—HCK—blood—hematologic cancer	0.000127	0.00718	CbGeAlD
Nilotinib—ABL2—blood—hematologic cancer	0.000126	0.00714	CbGeAlD
Nilotinib—ABCB1—Vincristine—hematologic cancer	0.000126	0.000779	CbGbCtD
Nilotinib—MAP4K1—testis—hematologic cancer	0.000126	0.00712	CbGeAlD
Nilotinib—UGT1A1—hematopoietic system—hematologic cancer	0.000126	0.00712	CbGeAlD
Nilotinib—CYP3A4—Vinorelbine—hematologic cancer	0.000125	0.000771	CbGbCtD
Nilotinib—HCK—bone marrow—hematologic cancer	0.000123	0.00695	CbGeAlD
Nilotinib—BRAF—lung—hematologic cancer	0.000122	0.00691	CbGeAlD
Nilotinib—CYP2C9—Cisplatin—hematologic cancer	0.000121	0.000749	CbGbCtD
Nilotinib—EPHB3—lung—hematologic cancer	0.000121	0.00685	CbGeAlD
Nilotinib—CYP2D6—Vinblastine—hematologic cancer	0.000121	0.000747	CbGbCtD
Nilotinib—TIE1—testis—hematologic cancer	0.00012	0.0068	CbGeAlD
Nilotinib—ABCB1—Cisplatin—hematologic cancer	0.000118	0.000727	CbGbCtD
Nilotinib—CSF1R—hematopoietic system—hematologic cancer	0.000116	0.00657	CbGeAlD
Nilotinib—ABCB1—Etoposide—hematologic cancer	0.000116	0.000714	CbGbCtD
Nilotinib—EPHA4—blood—hematologic cancer	0.000115	0.00653	CbGeAlD
Nilotinib—BRAF—testis—hematologic cancer	0.000115	0.00652	CbGeAlD
Nilotinib—EPHB3—testis—hematologic cancer	0.000114	0.00646	CbGeAlD
Nilotinib—CYP3A4—Triamcinolone—hematologic cancer	0.000114	0.000705	CbGbCtD
Nilotinib—Ponatinib—FGFR3—hematologic cancer	0.000112	0.0755	CrCbGaD
Nilotinib—MAPK11—lymph node—hematologic cancer	0.000112	0.00633	CbGeAlD
Nilotinib—HCK—lung—hematologic cancer	0.000111	0.0063	CbGeAlD
Nilotinib—CYP3A4—Dasatinib—hematologic cancer	0.000111	0.000687	CbGbCtD
Nilotinib—CDC42BPB—lymph node—hematologic cancer	0.000111	0.00628	CbGeAlD
Nilotinib—ABL2—lung—hematologic cancer	0.000111	0.00626	CbGeAlD
Nilotinib—CA3—bone marrow—hematologic cancer	0.00011	0.00624	CbGeAlD
Nilotinib—CYP3A4—Mitoxantrone—hematologic cancer	0.00011	0.000678	CbGbCtD
Nilotinib—MAPK14—blood—hematologic cancer	0.000106	0.00602	CbGeAlD
Nilotinib—LCK—blood—hematologic cancer	0.000106	0.00599	CbGeAlD
Nilotinib—FGR—blood—hematologic cancer	0.000106	0.00599	CbGeAlD
Nilotinib—KIT—hematopoietic system—hematologic cancer	0.000106	0.00597	CbGeAlD
Nilotinib—EPHA3—lymph node—hematologic cancer	0.000105	0.00596	CbGeAlD
Nilotinib—HCK—testis—hematologic cancer	0.000105	0.00594	CbGeAlD
Nilotinib—ABL2—testis—hematologic cancer	0.000104	0.0059	CbGeAlD
Nilotinib—PDGFRB—hematopoietic system—hematologic cancer	0.000103	0.00583	CbGeAlD
Nilotinib—MAPK14—bone marrow—hematologic cancer	0.000103	0.00582	CbGeAlD
Nilotinib—LCK—bone marrow—hematologic cancer	0.000103	0.0058	CbGeAlD
Nilotinib—FGR—bone marrow—hematologic cancer	0.000103	0.0058	CbGeAlD
Nilotinib—Ponatinib—RET—hematologic cancer	0.000102	0.0683	CrCbGaD
Nilotinib—EPHA4—lung—hematologic cancer	0.000101	0.00572	CbGeAlD
Nilotinib—EPHB4—blood—hematologic cancer	0.000101	0.00571	CbGeAlD
Nilotinib—MAPK8—lymph node—hematologic cancer	0.0001	0.00568	CbGeAlD
Nilotinib—PDGFRA—gonad—hematologic cancer	0.0001	0.00568	CbGeAlD
Nilotinib—CA3—lung—hematologic cancer	0.0001	0.00565	CbGeAlD
Nilotinib—EPHA2—blood—hematologic cancer	9.9e-05	0.0056	CbGeAlD
Nilotinib—CYP2C9—Dexamethasone—hematologic cancer	9.8e-05	0.000605	CbGbCtD
Nilotinib—CYP3A4—Betamethasone—hematologic cancer	9.79e-05	0.000605	CbGbCtD
Nilotinib—EPHB4—bone marrow—hematologic cancer	9.76e-05	0.00552	CbGeAlD
Nilotinib—CYP3A4—Prednisolone—hematologic cancer	9.66e-05	0.000597	CbGbCtD
Nilotinib—TEK—blood—hematologic cancer	9.66e-05	0.00546	CbGeAlD
Nilotinib—CA1—hematopoietic system—hematologic cancer	9.65e-05	0.00546	CbGeAlD
Nilotinib—EPHA4—testis—hematologic cancer	9.55e-05	0.0054	CbGeAlD
Nilotinib—ABCB1—Dexamethasone—hematologic cancer	9.51e-05	0.000587	CbGbCtD
Nilotinib—CA3—testis—hematologic cancer	9.43e-05	0.00533	CbGeAlD
Nilotinib—MAPK14—lung—hematologic cancer	9.33e-05	0.00528	CbGeAlD
Nilotinib—LCK—lung—hematologic cancer	9.29e-05	0.00525	CbGeAlD
Nilotinib—FGR—lung—hematologic cancer	9.29e-05	0.00525	CbGeAlD
Nilotinib—EPHB6—blood—hematologic cancer	9.23e-05	0.00522	CbGeAlD
Nilotinib—ABL1—hematopoietic system—hematologic cancer	9.19e-05	0.0052	CbGeAlD
Nilotinib—MAP4K1—lymph node—hematologic cancer	9.13e-05	0.00516	CbGeAlD
Nilotinib—CYP3A4—Prednisone—hematologic cancer	9.12e-05	0.000563	CbGbCtD
Nilotinib—CA9—testis—hematologic cancer	9.03e-05	0.00511	CbGeAlD
Nilotinib—CYP2D6—Dexamethasone—hematologic cancer	8.96e-05	0.000553	CbGbCtD
Nilotinib—EPHB4—lung—hematologic cancer	8.84e-05	0.005	CbGeAlD
Nilotinib—CSF1R—gonad—hematologic cancer	8.84e-05	0.005	CbGeAlD
Nilotinib—MAPK14—testis—hematologic cancer	8.8e-05	0.00498	CbGeAlD
Nilotinib—LCK—testis—hematologic cancer	8.77e-05	0.00496	CbGeAlD
Nilotinib—FGR—testis—hematologic cancer	8.77e-05	0.00496	CbGeAlD
Nilotinib—PDGFRA—blood—hematologic cancer	8.75e-05	0.00495	CbGeAlD
Nilotinib—TIE1—lymph node—hematologic cancer	8.71e-05	0.00493	CbGeAlD
Nilotinib—EPHA2—lung—hematologic cancer	8.68e-05	0.00491	CbGeAlD
Nilotinib—Imatinib—ABL2—hematologic cancer	8.66e-05	0.0581	CrCbGaD
Nilotinib—CYP3A4—Irinotecan—hematologic cancer	8.65e-05	0.000534	CbGbCtD
Nilotinib—TEK—lung—hematologic cancer	8.46e-05	0.00479	CbGeAlD
Nilotinib—BRAF—lymph node—hematologic cancer	8.35e-05	0.00472	CbGeAlD
Nilotinib—EPHB4—testis—hematologic cancer	8.35e-05	0.00472	CbGeAlD
Nilotinib—UGT1A1—blood—hematologic cancer	8.35e-05	0.00472	CbGeAlD
Nilotinib—EPHB3—lymph node—hematologic cancer	8.29e-05	0.00469	CbGeAlD
Nilotinib—Imatinib—LCK—hematologic cancer	8.26e-05	0.0554	CrCbGaD
Nilotinib—EPHA2—testis—hematologic cancer	8.19e-05	0.00463	CbGeAlD
Nilotinib—EPHB6—lung—hematologic cancer	8.09e-05	0.00457	CbGeAlD
Nilotinib—KIT—gonad—hematologic cancer	8.03e-05	0.00454	CbGeAlD
Nilotinib—TEK—testis—hematologic cancer	7.99e-05	0.00452	CbGeAlD
Nilotinib—MAP2K5—blood—hematologic cancer	7.89e-05	0.00446	CbGeAlD
Nilotinib—ABCB1—Doxorubicin—hematologic cancer	7.89e-05	0.000487	CbGbCtD
Nilotinib—ABL1—Topotecan—Irinotecan—hematologic cancer	7.87e-05	0.134	CbGdCrCtD
Nilotinib—PDGFRB—gonad—hematologic cancer	7.84e-05	0.00443	CbGeAlD
Nilotinib—CSF1R—blood—hematologic cancer	7.7e-05	0.00436	CbGeAlD
Nilotinib—CYP3A4—Vinblastine—hematologic cancer	7.69e-05	0.000475	CbGbCtD
Nilotinib—PDGFRA—lung—hematologic cancer	7.67e-05	0.00434	CbGeAlD
Nilotinib—ABCB1—Methotrexate—hematologic cancer	7.64e-05	0.000472	CbGbCtD
Nilotinib—EPHB6—testis—hematologic cancer	7.63e-05	0.00432	CbGeAlD
Nilotinib—HCK—lymph node—hematologic cancer	7.61e-05	0.00431	CbGeAlD
Nilotinib—ABL2—lymph node—hematologic cancer	7.57e-05	0.00428	CbGeAlD
Nilotinib—CYP3A4—Vincristine—hematologic cancer	7.56e-05	0.000467	CbGbCtD
Nilotinib—CSF1R—bone marrow—hematologic cancer	7.45e-05	0.00421	CbGeAlD
Nilotinib—CYP2D6—Doxorubicin—hematologic cancer	7.43e-05	0.000459	CbGbCtD
Nilotinib—PDGFRA—testis—hematologic cancer	7.24e-05	0.00409	CbGeAlD
Nilotinib—CA12—lung—hematologic cancer	7.08e-05	0.004	CbGeAlD
Nilotinib—KIT—blood—hematologic cancer	6.99e-05	0.00395	CbGeAlD
Nilotinib—ABL1—gonad—hematologic cancer	6.99e-05	0.00395	CbGeAlD
Nilotinib—CYP3A4—Etoposide—hematologic cancer	6.93e-05	0.000428	CbGbCtD
Nilotinib—EPHA4—lymph node—hematologic cancer	6.92e-05	0.00391	CbGeAlD
Nilotinib—MAP2K5—lung—hematologic cancer	6.92e-05	0.00391	CbGeAlD
Nilotinib—Ponatinib—PDGFRA—hematologic cancer	6.87e-05	0.0461	CrCbGaD
Nilotinib—CA3—lymph node—hematologic cancer	6.84e-05	0.00387	CbGeAlD
Nilotinib—PDGFRB—blood—hematologic cancer	6.83e-05	0.00386	CbGeAlD
Nilotinib—KIT—bone marrow—hematologic cancer	6.77e-05	0.00383	CbGeAlD
Nilotinib—CSF1R—lung—hematologic cancer	6.75e-05	0.00382	CbGeAlD
Nilotinib—PDGFRB—bone marrow—hematologic cancer	6.61e-05	0.00374	CbGeAlD
Nilotinib—MAP2K5—testis—hematologic cancer	6.53e-05	0.00369	CbGeAlD
Nilotinib—CA1—blood—hematologic cancer	6.4e-05	0.00362	CbGeAlD
Nilotinib—MAPK14—lymph node—hematologic cancer	6.38e-05	0.00361	CbGeAlD
Nilotinib—CSF1R—testis—hematologic cancer	6.37e-05	0.0036	CbGeAlD
Nilotinib—LCK—lymph node—hematologic cancer	6.36e-05	0.00359	CbGeAlD
Nilotinib—FGR—lymph node—hematologic cancer	6.36e-05	0.00359	CbGeAlD
Nilotinib—Ponatinib—ABL1—hematologic cancer	6.28e-05	0.0422	CrCbGaD
Nilotinib—CA2—hematopoietic system—hematologic cancer	6.26e-05	0.00354	CbGeAlD
Nilotinib—CA1—bone marrow—hematologic cancer	6.19e-05	0.0035	CbGeAlD
Nilotinib—KIT—lung—hematologic cancer	6.13e-05	0.00347	CbGeAlD
Nilotinib—ABL1—blood—hematologic cancer	6.09e-05	0.00344	CbGeAlD
Nilotinib—EPHB4—lymph node—hematologic cancer	6.05e-05	0.00342	CbGeAlD
Nilotinib—PDGFRB—lung—hematologic cancer	5.99e-05	0.00339	CbGeAlD
Nilotinib—CYP2C8—hematopoietic system—hematologic cancer	5.96e-05	0.00337	CbGeAlD
Nilotinib—EPHA2—lymph node—hematologic cancer	5.93e-05	0.00336	CbGeAlD
Nilotinib—ABL1—bone marrow—hematologic cancer	5.89e-05	0.00333	CbGeAlD
Nilotinib—TEK—lymph node—hematologic cancer	5.79e-05	0.00327	CbGeAlD
Nilotinib—KIT—testis—hematologic cancer	5.78e-05	0.00327	CbGeAlD
Nilotinib—CYP3A4—Dexamethasone—hematologic cancer	5.7e-05	0.000352	CbGbCtD
Nilotinib—Ponatinib—SRC—hematologic cancer	5.69e-05	0.0382	CrCbGaD
Nilotinib—PDGFRB—testis—hematologic cancer	5.65e-05	0.00319	CbGeAlD
Nilotinib—CA1—lung—hematologic cancer	5.61e-05	0.00317	CbGeAlD
Nilotinib—EPHB6—lymph node—hematologic cancer	5.53e-05	0.00313	CbGeAlD
Nilotinib—CYP2B6—hematopoietic system—hematologic cancer	5.35e-05	0.00302	CbGeAlD
Nilotinib—ABL1—lung—hematologic cancer	5.34e-05	0.00302	CbGeAlD
Nilotinib—ABL1—Doxorubicin—Daunorubicin—hematologic cancer	5.32e-05	0.0905	CbGdCrCtD
Nilotinib—ABL1—Epirubicin—Daunorubicin—hematologic cancer	5.32e-05	0.0905	CbGdCrCtD
Nilotinib—ABL1—Idarubicin—Daunorubicin—hematologic cancer	5.32e-05	0.0905	CbGdCrCtD
Nilotinib—CYP2C9—hematopoietic system—hematologic cancer	5.29e-05	0.00299	CbGeAlD
Nilotinib—PDGFRA—lymph node—hematologic cancer	5.25e-05	0.00297	CbGeAlD
Nilotinib—Ponatinib—KIT—hematologic cancer	5.04e-05	0.0338	CrCbGaD
Nilotinib—ABL1—testis—hematologic cancer	5.04e-05	0.00285	CbGeAlD
Nilotinib—CA4—blood—hematologic cancer	5e-05	0.00283	CbGeAlD
Nilotinib—Imatinib—CSF1R—hematologic cancer	4.97e-05	0.0334	CrCbGaD
Nilotinib—CA4—bone marrow—hematologic cancer	4.84e-05	0.00274	CbGeAlD
Nilotinib—MAP2K5—lymph node—hematologic cancer	4.73e-05	0.00268	CbGeAlD
Nilotinib—CYP3A4—Doxorubicin—hematologic cancer	4.72e-05	0.000292	CbGbCtD
Nilotinib—CSF1R—lymph node—hematologic cancer	4.62e-05	0.00261	CbGeAlD
Nilotinib—CA4—lung—hematologic cancer	4.38e-05	0.00248	CbGeAlD
Nilotinib—Imatinib—PDGFRB—hematologic cancer	4.34e-05	0.0291	CrCbGaD
Nilotinib—Imatinib—PDGFRA—hematologic cancer	4.23e-05	0.0284	CrCbGaD
Nilotinib—KIT—lymph node—hematologic cancer	4.19e-05	0.00237	CbGeAlD
Nilotinib—CA2—blood—hematologic cancer	4.15e-05	0.00234	CbGeAlD
Nilotinib—CA4—testis—hematologic cancer	4.14e-05	0.00234	CbGeAlD
Nilotinib—PDGFRB—lymph node—hematologic cancer	4.1e-05	0.00232	CbGeAlD
Nilotinib—CYP2B6—gonad—hematologic cancer	4.06e-05	0.0023	CbGeAlD
Nilotinib—CYP3A4—hematopoietic system—hematologic cancer	4.04e-05	0.00228	CbGeAlD
Nilotinib—ABL1—Epirubicin—Idarubicin—hematologic cancer	4.03e-05	0.0686	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Idarubicin—hematologic cancer	4.03e-05	0.0686	CbGdCrCtD
Nilotinib—ABL1—Doxorubicin—Idarubicin—hematologic cancer	4.03e-05	0.0686	CbGdCrCtD
Nilotinib—CA2—bone marrow—hematologic cancer	4.01e-05	0.00227	CbGeAlD
Nilotinib—CYP2D6—hematopoietic system—hematologic cancer	3.97e-05	0.00225	CbGeAlD
Nilotinib—CYP2C8—blood—hematologic cancer	3.95e-05	0.00223	CbGeAlD
Nilotinib—Imatinib—ABL1—hematologic cancer	3.87e-05	0.026	CrCbGaD
Nilotinib—ABCG2—blood—hematologic cancer	3.84e-05	0.00217	CbGeAlD
Nilotinib—CA1—lymph node—hematologic cancer	3.84e-05	0.00217	CbGeAlD
Nilotinib—ABCG2—bone marrow—hematologic cancer	3.71e-05	0.0021	CbGeAlD
Nilotinib—ABL1—lymph node—hematologic cancer	3.65e-05	0.00206	CbGeAlD
Nilotinib—CA2—lung—hematologic cancer	3.63e-05	0.00206	CbGeAlD
Nilotinib—CYP2B6—blood—hematologic cancer	3.54e-05	0.002	CbGeAlD
Nilotinib—CYP2C9—blood—hematologic cancer	3.51e-05	0.00198	CbGeAlD
Nilotinib—CA2—testis—hematologic cancer	3.43e-05	0.00194	CbGeAlD
Nilotinib—ABCG2—lung—hematologic cancer	3.37e-05	0.0019	CbGeAlD
Nilotinib—CYP2C8—testis—hematologic cancer	3.27e-05	0.00185	CbGeAlD
Nilotinib—ABCG2—testis—hematologic cancer	3.18e-05	0.0018	CbGeAlD
Nilotinib—CYP2B6—lung—hematologic cancer	3.1e-05	0.00176	CbGeAlD
Nilotinib—Imatinib—KIT—hematologic cancer	3.1e-05	0.0208	CrCbGaD
Nilotinib—CA4—lymph node—hematologic cancer	3e-05	0.0017	CbGeAlD
Nilotinib—Imatinib—CA9—hematologic cancer	2.98e-05	0.02	CrCbGaD
Nilotinib—CYP2B6—testis—hematologic cancer	2.93e-05	0.00166	CbGeAlD
Nilotinib—ABCB1—hematopoietic system—hematologic cancer	2.86e-05	0.00162	CbGeAlD
Nilotinib—Ponatinib—ABCG2—hematologic cancer	2.79e-05	0.0187	CrCbGaD
Nilotinib—CYP3A4—blood—hematologic cancer	2.67e-05	0.00151	CbGeAlD
Nilotinib—CYP2D6—blood—hematologic cancer	2.63e-05	0.00149	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Dexamethasone—hematologic cancer	2.52e-05	0.0429	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Betamethasone—hematologic cancer	2.52e-05	0.0429	CbGdCrCtD
Nilotinib—CA2—lymph node—hematologic cancer	2.49e-05	0.00141	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Triamcinolone—hematologic cancer	2.46e-05	0.0419	CbGdCrCtD
Nilotinib—Imatinib—SLC22A1—hematologic cancer	2.46e-05	0.0165	CrCbGaD
Nilotinib—EPHB2—Diflorasone—Prednisone—hematologic cancer	2.34e-05	0.0398	CbGdCrCtD
Nilotinib—ABCG2—lymph node—hematologic cancer	2.3e-05	0.0013	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Prednisolone—hematologic cancer	2.28e-05	0.0388	CbGdCrCtD
Nilotinib—CYP2D6—testis—hematologic cancer	2.18e-05	0.00123	CbGeAlD
Nilotinib—ABCB1—gonad—hematologic cancer	2.17e-05	0.00123	CbGeAlD
Nilotinib—ABCB1—blood—hematologic cancer	1.89e-05	0.00107	CbGeAlD
Nilotinib—ABL1—Daunorubicin—Epirubicin—hematologic cancer	1.85e-05	0.0315	CbGdCrCtD
Nilotinib—ABL1—Idarubicin—Epirubicin—hematologic cancer	1.85e-05	0.0315	CbGdCrCtD
Nilotinib—ABL1—Doxorubicin—Epirubicin—hematologic cancer	1.85e-05	0.0315	CbGdCrCtD
Nilotinib—ABCB1—bone marrow—hematologic cancer	1.83e-05	0.00104	CbGeAlD
Nilotinib—Imatinib—ABCG2—hematologic cancer	1.72e-05	0.0115	CrCbGaD
Nilotinib—ABL1—Epirubicin—Doxorubicin—hematologic cancer	1.71e-05	0.0292	CbGdCrCtD
Nilotinib—ABL1—Idarubicin—Doxorubicin—hematologic cancer	1.71e-05	0.0292	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Doxorubicin—hematologic cancer	1.71e-05	0.0292	CbGdCrCtD
Nilotinib—ABCB1—lung—hematologic cancer	1.66e-05	0.000938	CbGeAlD
Nilotinib—ABCB1—testis—hematologic cancer	1.57e-05	0.000885	CbGeAlD
Nilotinib—Ponatinib—ABCB1—hematologic cancer	1.16e-05	0.0078	CrCbGaD
Nilotinib—ABCB1—lymph node—hematologic cancer	1.14e-05	0.000642	CbGeAlD
Nilotinib—Imatinib—ALB—hematologic cancer	7.5e-06	0.00503	CrCbGaD
Nilotinib—Imatinib—ABCB1—hematologic cancer	7.15e-06	0.0048	CrCbGaD
Nilotinib—Erythema multiforme—Doxorubicin—hematologic cancer	2.16e-06	4.4e-05	CcSEcCtD
Nilotinib—Rash—Cisplatin—hematologic cancer	2.15e-06	4.39e-05	CcSEcCtD
Nilotinib—Dermatitis—Cisplatin—hematologic cancer	2.15e-06	4.39e-05	CcSEcCtD
Nilotinib—Erythema—Epirubicin—hematologic cancer	2.15e-06	4.38e-05	CcSEcCtD
Nilotinib—Malnutrition—Epirubicin—hematologic cancer	2.15e-06	4.38e-05	CcSEcCtD
Nilotinib—Diarrhoea—Etoposide—hematologic cancer	2.14e-06	4.37e-05	CcSEcCtD
Nilotinib—Anorexia—Prednisone—hematologic cancer	2.14e-06	4.36e-05	CcSEcCtD
Nilotinib—Eye disorder—Doxorubicin—hematologic cancer	2.13e-06	4.35e-05	CcSEcCtD
Nilotinib—Ill-defined disorder—Methotrexate—hematologic cancer	2.13e-06	4.35e-05	CcSEcCtD
Nilotinib—Tinnitus—Doxorubicin—hematologic cancer	2.13e-06	4.34e-05	CcSEcCtD
Nilotinib—Anaemia—Methotrexate—hematologic cancer	2.12e-06	4.33e-05	CcSEcCtD
Nilotinib—Feeling abnormal—Dexamethasone—hematologic cancer	2.12e-06	4.33e-05	CcSEcCtD
Nilotinib—Feeling abnormal—Betamethasone—hematologic cancer	2.12e-06	4.33e-05	CcSEcCtD
Nilotinib—Cardiac disorder—Doxorubicin—hematologic cancer	2.12e-06	4.32e-05	CcSEcCtD
Nilotinib—Flushing—Doxorubicin—hematologic cancer	2.12e-06	4.32e-05	CcSEcCtD
Nilotinib—Flatulence—Epirubicin—hematologic cancer	2.12e-06	4.32e-05	CcSEcCtD
Nilotinib—Gastrointestinal pain—Betamethasone—hematologic cancer	2.11e-06	4.29e-05	CcSEcCtD
Nilotinib—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.11e-06	4.29e-05	CcSEcCtD
Nilotinib—Dysgeusia—Epirubicin—hematologic cancer	2.1e-06	4.29e-05	CcSEcCtD
Nilotinib—Hypersensitivity—Triamcinolone—hematologic cancer	2.09e-06	4.26e-05	CcSEcCtD
Nilotinib—Back pain—Epirubicin—hematologic cancer	2.08e-06	4.24e-05	CcSEcCtD
Nilotinib—Angiopathy—Doxorubicin—hematologic cancer	2.07e-06	4.23e-05	CcSEcCtD
Nilotinib—Malaise—Methotrexate—hematologic cancer	2.07e-06	4.22e-05	CcSEcCtD
Nilotinib—Dizziness—Etoposide—hematologic cancer	2.07e-06	4.22e-05	CcSEcCtD
Nilotinib—Muscle spasms—Epirubicin—hematologic cancer	2.07e-06	4.21e-05	CcSEcCtD
Nilotinib—Immune system disorder—Doxorubicin—hematologic cancer	2.06e-06	4.21e-05	CcSEcCtD
Nilotinib—Vertigo—Methotrexate—hematologic cancer	2.06e-06	4.21e-05	CcSEcCtD
Nilotinib—Mediastinal disorder—Doxorubicin—hematologic cancer	2.06e-06	4.2e-05	CcSEcCtD
Nilotinib—Leukopenia—Methotrexate—hematologic cancer	2.06e-06	4.19e-05	CcSEcCtD
Nilotinib—Chills—Doxorubicin—hematologic cancer	2.05e-06	4.18e-05	CcSEcCtD
Nilotinib—Urticaria—Betamethasone—hematologic cancer	2.05e-06	4.17e-05	CcSEcCtD
Nilotinib—Urticaria—Dexamethasone—hematologic cancer	2.05e-06	4.17e-05	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.04e-06	4.17e-05	CcSEcCtD
Nilotinib—Dizziness—Prednisolone—hematologic cancer	2.04e-06	4.16e-05	CcSEcCtD
Nilotinib—Arrhythmia—Doxorubicin—hematologic cancer	2.04e-06	4.16e-05	CcSEcCtD
Nilotinib—Asthenia—Triamcinolone—hematologic cancer	2.04e-06	4.15e-05	CcSEcCtD
Nilotinib—Abdominal pain—Dexamethasone—hematologic cancer	2.04e-06	4.15e-05	CcSEcCtD
Nilotinib—Body temperature increased—Dexamethasone—hematologic cancer	2.04e-06	4.15e-05	CcSEcCtD
Nilotinib—Abdominal pain—Betamethasone—hematologic cancer	2.04e-06	4.15e-05	CcSEcCtD
Nilotinib—Body temperature increased—Betamethasone—hematologic cancer	2.04e-06	4.15e-05	CcSEcCtD
Nilotinib—Nausea—Cisplatin—hematologic cancer	2.03e-06	4.14e-05	CcSEcCtD
Nilotinib—Insomnia—Prednisone—hematologic cancer	2.03e-06	4.14e-05	CcSEcCtD
Nilotinib—Vision blurred—Epirubicin—hematologic cancer	2.03e-06	4.13e-05	CcSEcCtD
Nilotinib—Alopecia—Doxorubicin—hematologic cancer	2.02e-06	4.12e-05	CcSEcCtD
Nilotinib—Paraesthesia—Prednisone—hematologic cancer	2.01e-06	4.11e-05	CcSEcCtD
Nilotinib—Pruritus—Triamcinolone—hematologic cancer	2.01e-06	4.09e-05	CcSEcCtD
Nilotinib—Cough—Methotrexate—hematologic cancer	2e-06	4.09e-05	CcSEcCtD
Nilotinib—Mental disorder—Doxorubicin—hematologic cancer	2e-06	4.08e-05	CcSEcCtD
Nilotinib—Ill-defined disorder—Epirubicin—hematologic cancer	1.99e-06	4.07e-05	CcSEcCtD
Nilotinib—Vomiting—Etoposide—hematologic cancer	1.99e-06	4.06e-05	CcSEcCtD
Nilotinib—Erythema—Doxorubicin—hematologic cancer	1.99e-06	4.06e-05	CcSEcCtD
Nilotinib—Malnutrition—Doxorubicin—hematologic cancer	1.99e-06	4.06e-05	CcSEcCtD
Nilotinib—Anaemia—Epirubicin—hematologic cancer	1.99e-06	4.05e-05	CcSEcCtD
Nilotinib—Dyspepsia—Prednisone—hematologic cancer	1.97e-06	4.03e-05	CcSEcCtD
Nilotinib—Rash—Etoposide—hematologic cancer	1.97e-06	4.02e-05	CcSEcCtD
Nilotinib—Dermatitis—Etoposide—hematologic cancer	1.97e-06	4.02e-05	CcSEcCtD
Nilotinib—Headache—Etoposide—hematologic cancer	1.96e-06	4e-05	CcSEcCtD
Nilotinib—Flatulence—Doxorubicin—hematologic cancer	1.96e-06	4e-05	CcSEcCtD
Nilotinib—Arthralgia—Methotrexate—hematologic cancer	1.96e-06	3.99e-05	CcSEcCtD
Nilotinib—Chest pain—Methotrexate—hematologic cancer	1.96e-06	3.99e-05	CcSEcCtD
Nilotinib—Myalgia—Methotrexate—hematologic cancer	1.96e-06	3.99e-05	CcSEcCtD
Nilotinib—Decreased appetite—Prednisone—hematologic cancer	1.95e-06	3.98e-05	CcSEcCtD
Nilotinib—Dysgeusia—Doxorubicin—hematologic cancer	1.95e-06	3.97e-05	CcSEcCtD
Nilotinib—Rash—Prednisolone—hematologic cancer	1.95e-06	3.97e-05	CcSEcCtD
Nilotinib—Dermatitis—Prednisolone—hematologic cancer	1.94e-06	3.96e-05	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.94e-06	3.96e-05	CcSEcCtD
Nilotinib—Malaise—Epirubicin—hematologic cancer	1.94e-06	3.95e-05	CcSEcCtD
Nilotinib—Fatigue—Prednisone—hematologic cancer	1.93e-06	3.94e-05	CcSEcCtD
Nilotinib—Headache—Prednisolone—hematologic cancer	1.93e-06	3.94e-05	CcSEcCtD
Nilotinib—Discomfort—Methotrexate—hematologic cancer	1.93e-06	3.94e-05	CcSEcCtD
Nilotinib—Vertigo—Epirubicin—hematologic cancer	1.93e-06	3.94e-05	CcSEcCtD
Nilotinib—Syncope—Epirubicin—hematologic cancer	1.93e-06	3.93e-05	CcSEcCtD
Nilotinib—Leukopenia—Epirubicin—hematologic cancer	1.92e-06	3.92e-05	CcSEcCtD
Nilotinib—Back pain—Doxorubicin—hematologic cancer	1.92e-06	3.92e-05	CcSEcCtD
Nilotinib—Constipation—Prednisone—hematologic cancer	1.92e-06	3.91e-05	CcSEcCtD
Nilotinib—Muscle spasms—Doxorubicin—hematologic cancer	1.91e-06	3.9e-05	CcSEcCtD
Nilotinib—Palpitations—Epirubicin—hematologic cancer	1.9e-06	3.87e-05	CcSEcCtD
Nilotinib—Confusional state—Methotrexate—hematologic cancer	1.89e-06	3.85e-05	CcSEcCtD
Nilotinib—Loss of consciousness—Epirubicin—hematologic cancer	1.89e-06	3.85e-05	CcSEcCtD
Nilotinib—Dizziness—Triamcinolone—hematologic cancer	1.88e-06	3.83e-05	CcSEcCtD
Nilotinib—Cough—Epirubicin—hematologic cancer	1.88e-06	3.82e-05	CcSEcCtD
Nilotinib—Vision blurred—Doxorubicin—hematologic cancer	1.87e-06	3.82e-05	CcSEcCtD
Nilotinib—Infection—Methotrexate—hematologic cancer	1.86e-06	3.8e-05	CcSEcCtD
Nilotinib—Nausea—Etoposide—hematologic cancer	1.86e-06	3.79e-05	CcSEcCtD
Nilotinib—Hypertension—Epirubicin—hematologic cancer	1.86e-06	3.78e-05	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisone—hematologic cancer	1.85e-06	3.77e-05	CcSEcCtD
Nilotinib—Asthenia—Dexamethasone—hematologic cancer	1.85e-06	3.77e-05	CcSEcCtD
Nilotinib—Asthenia—Betamethasone—hematologic cancer	1.85e-06	3.77e-05	CcSEcCtD
Nilotinib—Ill-defined disorder—Doxorubicin—hematologic cancer	1.84e-06	3.76e-05	CcSEcCtD
Nilotinib—Nervous system disorder—Methotrexate—hematologic cancer	1.84e-06	3.75e-05	CcSEcCtD
Nilotinib—Anaemia—Doxorubicin—hematologic cancer	1.84e-06	3.75e-05	CcSEcCtD
Nilotinib—Thrombocytopenia—Methotrexate—hematologic cancer	1.84e-06	3.74e-05	CcSEcCtD
Nilotinib—Gastrointestinal pain—Prednisone—hematologic cancer	1.83e-06	3.74e-05	CcSEcCtD
Nilotinib—Nausea—Prednisolone—hematologic cancer	1.83e-06	3.74e-05	CcSEcCtD
Nilotinib—Myalgia—Epirubicin—hematologic cancer	1.83e-06	3.73e-05	CcSEcCtD
Nilotinib—Arthralgia—Epirubicin—hematologic cancer	1.83e-06	3.73e-05	CcSEcCtD
Nilotinib—Chest pain—Epirubicin—hematologic cancer	1.83e-06	3.73e-05	CcSEcCtD
Nilotinib—Anxiety—Epirubicin—hematologic cancer	1.82e-06	3.72e-05	CcSEcCtD
Nilotinib—Pruritus—Betamethasone—hematologic cancer	1.82e-06	3.72e-05	CcSEcCtD
Nilotinib—Pruritus—Dexamethasone—hematologic cancer	1.82e-06	3.72e-05	CcSEcCtD
Nilotinib—Skin disorder—Methotrexate—hematologic cancer	1.82e-06	3.71e-05	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.82e-06	3.71e-05	CcSEcCtD
Nilotinib—Hyperhidrosis—Methotrexate—hematologic cancer	1.81e-06	3.69e-05	CcSEcCtD
Nilotinib—Discomfort—Epirubicin—hematologic cancer	1.81e-06	3.69e-05	CcSEcCtD
Nilotinib—Vomiting—Triamcinolone—hematologic cancer	1.8e-06	3.68e-05	CcSEcCtD
Nilotinib—Malaise—Doxorubicin—hematologic cancer	1.79e-06	3.66e-05	CcSEcCtD
Nilotinib—Rash—Triamcinolone—hematologic cancer	1.79e-06	3.65e-05	CcSEcCtD
Nilotinib—Dry mouth—Epirubicin—hematologic cancer	1.79e-06	3.65e-05	CcSEcCtD
Nilotinib—Dermatitis—Triamcinolone—hematologic cancer	1.79e-06	3.65e-05	CcSEcCtD
Nilotinib—Vertigo—Doxorubicin—hematologic cancer	1.79e-06	3.64e-05	CcSEcCtD
Nilotinib—Anorexia—Methotrexate—hematologic cancer	1.79e-06	3.64e-05	CcSEcCtD
Nilotinib—Syncope—Doxorubicin—hematologic cancer	1.78e-06	3.64e-05	CcSEcCtD
Nilotinib—Urticaria—Prednisone—hematologic cancer	1.78e-06	3.63e-05	CcSEcCtD
Nilotinib—Leukopenia—Doxorubicin—hematologic cancer	1.78e-06	3.63e-05	CcSEcCtD
Nilotinib—Headache—Triamcinolone—hematologic cancer	1.78e-06	3.63e-05	CcSEcCtD
Nilotinib—Body temperature increased—Prednisone—hematologic cancer	1.77e-06	3.62e-05	CcSEcCtD
Nilotinib—Abdominal pain—Prednisone—hematologic cancer	1.77e-06	3.62e-05	CcSEcCtD
Nilotinib—Confusional state—Epirubicin—hematologic cancer	1.77e-06	3.61e-05	CcSEcCtD
Nilotinib—Diarrhoea—Betamethasone—hematologic cancer	1.76e-06	3.59e-05	CcSEcCtD
Nilotinib—Diarrhoea—Dexamethasone—hematologic cancer	1.76e-06	3.59e-05	CcSEcCtD
Nilotinib—Palpitations—Doxorubicin—hematologic cancer	1.76e-06	3.58e-05	CcSEcCtD
Nilotinib—Oedema—Epirubicin—hematologic cancer	1.75e-06	3.58e-05	CcSEcCtD
Nilotinib—Hypotension—Methotrexate—hematologic cancer	1.75e-06	3.57e-05	CcSEcCtD
Nilotinib—Loss of consciousness—Doxorubicin—hematologic cancer	1.75e-06	3.56e-05	CcSEcCtD
Nilotinib—Infection—Epirubicin—hematologic cancer	1.74e-06	3.55e-05	CcSEcCtD
Nilotinib—Cough—Doxorubicin—hematologic cancer	1.74e-06	3.54e-05	CcSEcCtD
Nilotinib—Shock—Epirubicin—hematologic cancer	1.73e-06	3.52e-05	CcSEcCtD
Nilotinib—Nervous system disorder—Epirubicin—hematologic cancer	1.72e-06	3.51e-05	CcSEcCtD
Nilotinib—Thrombocytopenia—Epirubicin—hematologic cancer	1.72e-06	3.5e-05	CcSEcCtD
Nilotinib—Hypertension—Doxorubicin—hematologic cancer	1.72e-06	3.5e-05	CcSEcCtD
Nilotinib—Tachycardia—Epirubicin—hematologic cancer	1.71e-06	3.49e-05	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.71e-06	3.48e-05	CcSEcCtD
Nilotinib—Skin disorder—Epirubicin—hematologic cancer	1.7e-06	3.47e-05	CcSEcCtD
Nilotinib—Dizziness—Dexamethasone—hematologic cancer	1.7e-06	3.47e-05	CcSEcCtD
Nilotinib—Dizziness—Betamethasone—hematologic cancer	1.7e-06	3.47e-05	CcSEcCtD
Nilotinib—Hyperhidrosis—Epirubicin—hematologic cancer	1.7e-06	3.46e-05	CcSEcCtD
Nilotinib—Insomnia—Methotrexate—hematologic cancer	1.7e-06	3.46e-05	CcSEcCtD
Nilotinib—Chest pain—Doxorubicin—hematologic cancer	1.69e-06	3.45e-05	CcSEcCtD
Nilotinib—Arthralgia—Doxorubicin—hematologic cancer	1.69e-06	3.45e-05	CcSEcCtD
Nilotinib—Myalgia—Doxorubicin—hematologic cancer	1.69e-06	3.45e-05	CcSEcCtD
Nilotinib—Anxiety—Doxorubicin—hematologic cancer	1.69e-06	3.44e-05	CcSEcCtD
Nilotinib—Nausea—Triamcinolone—hematologic cancer	1.69e-06	3.44e-05	CcSEcCtD
Nilotinib—Paraesthesia—Methotrexate—hematologic cancer	1.68e-06	3.43e-05	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.68e-06	3.43e-05	CcSEcCtD
Nilotinib—Discomfort—Doxorubicin—hematologic cancer	1.67e-06	3.41e-05	CcSEcCtD
Nilotinib—Anorexia—Epirubicin—hematologic cancer	1.67e-06	3.41e-05	CcSEcCtD
Nilotinib—Dyspnoea—Methotrexate—hematologic cancer	1.67e-06	3.41e-05	CcSEcCtD
Nilotinib—Dry mouth—Doxorubicin—hematologic cancer	1.66e-06	3.38e-05	CcSEcCtD
Nilotinib—Hypersensitivity—Prednisone—hematologic cancer	1.65e-06	3.37e-05	CcSEcCtD
Nilotinib—Dyspepsia—Methotrexate—hematologic cancer	1.65e-06	3.36e-05	CcSEcCtD
Nilotinib—Hypotension—Epirubicin—hematologic cancer	1.64e-06	3.34e-05	CcSEcCtD
Nilotinib—Vomiting—Betamethasone—hematologic cancer	1.64e-06	3.34e-05	CcSEcCtD
Nilotinib—Vomiting—Dexamethasone—hematologic cancer	1.64e-06	3.34e-05	CcSEcCtD
Nilotinib—Confusional state—Doxorubicin—hematologic cancer	1.64e-06	3.34e-05	CcSEcCtD
Nilotinib—Decreased appetite—Methotrexate—hematologic cancer	1.63e-06	3.32e-05	CcSEcCtD
Nilotinib—Rash—Dexamethasone—hematologic cancer	1.62e-06	3.31e-05	CcSEcCtD
Nilotinib—Rash—Betamethasone—hematologic cancer	1.62e-06	3.31e-05	CcSEcCtD
Nilotinib—Oedema—Doxorubicin—hematologic cancer	1.62e-06	3.31e-05	CcSEcCtD
Nilotinib—Dermatitis—Betamethasone—hematologic cancer	1.62e-06	3.31e-05	CcSEcCtD
Nilotinib—Dermatitis—Dexamethasone—hematologic cancer	1.62e-06	3.31e-05	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.62e-06	3.3e-05	CcSEcCtD
Nilotinib—Fatigue—Methotrexate—hematologic cancer	1.62e-06	3.3e-05	CcSEcCtD
Nilotinib—Headache—Betamethasone—hematologic cancer	1.61e-06	3.29e-05	CcSEcCtD
Nilotinib—Headache—Dexamethasone—hematologic cancer	1.61e-06	3.29e-05	CcSEcCtD
Nilotinib—Infection—Doxorubicin—hematologic cancer	1.61e-06	3.29e-05	CcSEcCtD
Nilotinib—Asthenia—Prednisone—hematologic cancer	1.61e-06	3.28e-05	CcSEcCtD
Nilotinib—Pain—Methotrexate—hematologic cancer	1.6e-06	3.27e-05	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.6e-06	3.26e-05	CcSEcCtD
Nilotinib—Shock—Doxorubicin—hematologic cancer	1.6e-06	3.26e-05	CcSEcCtD
Nilotinib—Nervous system disorder—Doxorubicin—hematologic cancer	1.59e-06	3.25e-05	CcSEcCtD
Nilotinib—Thrombocytopenia—Doxorubicin—hematologic cancer	1.59e-06	3.24e-05	CcSEcCtD
Nilotinib—Pruritus—Prednisone—hematologic cancer	1.59e-06	3.24e-05	CcSEcCtD
Nilotinib—Insomnia—Epirubicin—hematologic cancer	1.59e-06	3.24e-05	CcSEcCtD
Nilotinib—Tachycardia—Doxorubicin—hematologic cancer	1.58e-06	3.23e-05	CcSEcCtD
Nilotinib—Skin disorder—Doxorubicin—hematologic cancer	1.58e-06	3.21e-05	CcSEcCtD
Nilotinib—Paraesthesia—Epirubicin—hematologic cancer	1.57e-06	3.21e-05	CcSEcCtD
Nilotinib—Hyperhidrosis—Doxorubicin—hematologic cancer	1.57e-06	3.2e-05	CcSEcCtD
Nilotinib—Dyspnoea—Epirubicin—hematologic cancer	1.56e-06	3.19e-05	CcSEcCtD
Nilotinib—Anorexia—Doxorubicin—hematologic cancer	1.55e-06	3.15e-05	CcSEcCtD
Nilotinib—Feeling abnormal—Methotrexate—hematologic cancer	1.54e-06	3.15e-05	CcSEcCtD
Nilotinib—Dyspepsia—Epirubicin—hematologic cancer	1.54e-06	3.15e-05	CcSEcCtD
Nilotinib—Diarrhoea—Prednisone—hematologic cancer	1.53e-06	3.13e-05	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methotrexate—hematologic cancer	1.53e-06	3.13e-05	CcSEcCtD
Nilotinib—Nausea—Dexamethasone—hematologic cancer	1.53e-06	3.12e-05	CcSEcCtD
Nilotinib—Nausea—Betamethasone—hematologic cancer	1.53e-06	3.12e-05	CcSEcCtD
Nilotinib—Decreased appetite—Epirubicin—hematologic cancer	1.52e-06	3.11e-05	CcSEcCtD
Nilotinib—Hypotension—Doxorubicin—hematologic cancer	1.52e-06	3.09e-05	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.51e-06	3.09e-05	CcSEcCtD
Nilotinib—Fatigue—Epirubicin—hematologic cancer	1.51e-06	3.08e-05	CcSEcCtD
Nilotinib—Pain—Epirubicin—hematologic cancer	1.5e-06	3.06e-05	CcSEcCtD
Nilotinib—Constipation—Epirubicin—hematologic cancer	1.5e-06	3.06e-05	CcSEcCtD
Nilotinib—Urticaria—Methotrexate—hematologic cancer	1.49e-06	3.04e-05	CcSEcCtD
Nilotinib—Dizziness—Prednisone—hematologic cancer	1.48e-06	3.02e-05	CcSEcCtD
Nilotinib—Abdominal pain—Methotrexate—hematologic cancer	1.48e-06	3.02e-05	CcSEcCtD
Nilotinib—Body temperature increased—Methotrexate—hematologic cancer	1.48e-06	3.02e-05	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.48e-06	3.02e-05	CcSEcCtD
Nilotinib—Insomnia—Doxorubicin—hematologic cancer	1.47e-06	2.99e-05	CcSEcCtD
Nilotinib—Paraesthesia—Doxorubicin—hematologic cancer	1.46e-06	2.97e-05	CcSEcCtD
Nilotinib—Dyspnoea—Doxorubicin—hematologic cancer	1.45e-06	2.95e-05	CcSEcCtD
Nilotinib—Feeling abnormal—Epirubicin—hematologic cancer	1.45e-06	2.95e-05	CcSEcCtD
Nilotinib—Gastrointestinal pain—Epirubicin—hematologic cancer	1.43e-06	2.92e-05	CcSEcCtD
Nilotinib—Dyspepsia—Doxorubicin—hematologic cancer	1.43e-06	2.91e-05	CcSEcCtD
Nilotinib—Vomiting—Prednisone—hematologic cancer	1.43e-06	2.91e-05	CcSEcCtD
Nilotinib—Rash—Prednisone—hematologic cancer	1.41e-06	2.88e-05	CcSEcCtD
Nilotinib—Dermatitis—Prednisone—hematologic cancer	1.41e-06	2.88e-05	CcSEcCtD
Nilotinib—Decreased appetite—Doxorubicin—hematologic cancer	1.41e-06	2.88e-05	CcSEcCtD
Nilotinib—Headache—Prednisone—hematologic cancer	1.4e-06	2.86e-05	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.4e-06	2.86e-05	CcSEcCtD
Nilotinib—Fatigue—Doxorubicin—hematologic cancer	1.4e-06	2.85e-05	CcSEcCtD
Nilotinib—Urticaria—Epirubicin—hematologic cancer	1.39e-06	2.84e-05	CcSEcCtD
Nilotinib—Pain—Doxorubicin—hematologic cancer	1.39e-06	2.83e-05	CcSEcCtD
Nilotinib—Constipation—Doxorubicin—hematologic cancer	1.39e-06	2.83e-05	CcSEcCtD
Nilotinib—Abdominal pain—Epirubicin—hematologic cancer	1.39e-06	2.83e-05	CcSEcCtD
Nilotinib—Body temperature increased—Epirubicin—hematologic cancer	1.39e-06	2.83e-05	CcSEcCtD
Nilotinib—Hypersensitivity—Methotrexate—hematologic cancer	1.38e-06	2.82e-05	CcSEcCtD
Nilotinib—Asthenia—Methotrexate—hematologic cancer	1.34e-06	2.74e-05	CcSEcCtD
Nilotinib—Feeling abnormal—Doxorubicin—hematologic cancer	1.34e-06	2.73e-05	CcSEcCtD
Nilotinib—Nausea—Prednisone—hematologic cancer	1.33e-06	2.72e-05	CcSEcCtD
Nilotinib—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.33e-06	2.71e-05	CcSEcCtD
Nilotinib—Pruritus—Methotrexate—hematologic cancer	1.33e-06	2.7e-05	CcSEcCtD
Nilotinib—Hypersensitivity—Epirubicin—hematologic cancer	1.29e-06	2.64e-05	CcSEcCtD
Nilotinib—Urticaria—Doxorubicin—hematologic cancer	1.29e-06	2.63e-05	CcSEcCtD
Nilotinib—Abdominal pain—Doxorubicin—hematologic cancer	1.28e-06	2.62e-05	CcSEcCtD
Nilotinib—Body temperature increased—Doxorubicin—hematologic cancer	1.28e-06	2.62e-05	CcSEcCtD
Nilotinib—Diarrhoea—Methotrexate—hematologic cancer	1.28e-06	2.62e-05	CcSEcCtD
Nilotinib—Asthenia—Epirubicin—hematologic cancer	1.26e-06	2.57e-05	CcSEcCtD
Nilotinib—Pruritus—Epirubicin—hematologic cancer	1.24e-06	2.53e-05	CcSEcCtD
Nilotinib—Dizziness—Methotrexate—hematologic cancer	1.24e-06	2.53e-05	CcSEcCtD
Nilotinib—Diarrhoea—Epirubicin—hematologic cancer	1.2e-06	2.45e-05	CcSEcCtD
Nilotinib—Hypersensitivity—Doxorubicin—hematologic cancer	1.2e-06	2.44e-05	CcSEcCtD
Nilotinib—Vomiting—Methotrexate—hematologic cancer	1.19e-06	2.43e-05	CcSEcCtD
Nilotinib—Rash—Methotrexate—hematologic cancer	1.18e-06	2.41e-05	CcSEcCtD
Nilotinib—Dermatitis—Methotrexate—hematologic cancer	1.18e-06	2.41e-05	CcSEcCtD
Nilotinib—Headache—Methotrexate—hematologic cancer	1.17e-06	2.39e-05	CcSEcCtD
Nilotinib—Asthenia—Doxorubicin—hematologic cancer	1.16e-06	2.37e-05	CcSEcCtD
Nilotinib—Dizziness—Epirubicin—hematologic cancer	1.16e-06	2.37e-05	CcSEcCtD
Nilotinib—Pruritus—Doxorubicin—hematologic cancer	1.15e-06	2.34e-05	CcSEcCtD
Nilotinib—Vomiting—Epirubicin—hematologic cancer	1.12e-06	2.27e-05	CcSEcCtD
Nilotinib—Nausea—Methotrexate—hematologic cancer	1.11e-06	2.27e-05	CcSEcCtD
Nilotinib—Diarrhoea—Doxorubicin—hematologic cancer	1.11e-06	2.26e-05	CcSEcCtD
Nilotinib—Rash—Epirubicin—hematologic cancer	1.11e-06	2.26e-05	CcSEcCtD
Nilotinib—Dermatitis—Epirubicin—hematologic cancer	1.1e-06	2.25e-05	CcSEcCtD
Nilotinib—Headache—Epirubicin—hematologic cancer	1.1e-06	2.24e-05	CcSEcCtD
Nilotinib—Dizziness—Doxorubicin—hematologic cancer	1.07e-06	2.19e-05	CcSEcCtD
Nilotinib—Nausea—Epirubicin—hematologic cancer	1.04e-06	2.12e-05	CcSEcCtD
Nilotinib—Vomiting—Doxorubicin—hematologic cancer	1.03e-06	2.1e-05	CcSEcCtD
Nilotinib—Rash—Doxorubicin—hematologic cancer	1.02e-06	2.09e-05	CcSEcCtD
Nilotinib—Dermatitis—Doxorubicin—hematologic cancer	1.02e-06	2.08e-05	CcSEcCtD
Nilotinib—Headache—Doxorubicin—hematologic cancer	1.02e-06	2.07e-05	CcSEcCtD
Nilotinib—Nausea—Doxorubicin—hematologic cancer	9.64e-07	1.97e-05	CcSEcCtD
Nilotinib—ABCB1—Metabolism—GSTM1—hematologic cancer	8.18e-08	1.86e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NCOR1—hematologic cancer	8.18e-08	1.86e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGF2—hematologic cancer	8.16e-08	1.86e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—hematologic cancer	8.15e-08	1.86e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ENO2—hematologic cancer	8.15e-08	1.86e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCND1—hematologic cancer	8.11e-08	1.85e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—HRAS—hematologic cancer	8.1e-08	1.85e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PIK3CA—hematologic cancer	8.1e-08	1.85e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—JUN—hematologic cancer	8.1e-08	1.84e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HRAS—hematologic cancer	8.07e-08	1.84e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1B—hematologic cancer	8.06e-08	1.84e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PIK3CA—hematologic cancer	8.06e-08	1.84e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3R1—hematologic cancer	8.05e-08	1.83e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	8.04e-08	1.83e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—hematologic cancer	8.02e-08	1.83e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CDKN1A—hematologic cancer	8.02e-08	1.83e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MAPK3—hematologic cancer	8.01e-08	1.83e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PTEN—hematologic cancer	8e-08	1.82e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KRAS—hematologic cancer	7.99e-08	1.82e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—STAT3—hematologic cancer	7.94e-08	1.81e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ABCB1—hematologic cancer	7.94e-08	1.81e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NRAS—hematologic cancer	7.92e-08	1.8e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—hematologic cancer	7.92e-08	1.8e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—hematologic cancer	7.91e-08	1.8e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KRAS—hematologic cancer	7.91e-08	1.8e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTT1—hematologic cancer	7.91e-08	1.8e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—HRAS—hematologic cancer	7.9e-08	1.8e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CASP3—hematologic cancer	7.9e-08	1.8e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—hematologic cancer	7.89e-08	1.8e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ABCB1—hematologic cancer	7.87e-08	1.79e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HRAS—hematologic cancer	7.87e-08	1.79e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CDKN1A—hematologic cancer	7.85e-08	1.79e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MAPK3—hematologic cancer	7.83e-08	1.78e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PTEN—hematologic cancer	7.83e-08	1.78e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK8—hematologic cancer	7.82e-08	1.78e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—JAK2—hematologic cancer	7.82e-08	1.78e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—hematologic cancer	7.79e-08	1.78e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—hematologic cancer	7.77e-08	1.77e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—hematologic cancer	7.75e-08	1.77e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SDC1—hematologic cancer	7.73e-08	1.76e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—hematologic cancer	7.73e-08	1.76e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—hematologic cancer	7.72e-08	1.76e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTM1—hematologic cancer	7.71e-08	1.76e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NCOR1—hematologic cancer	7.71e-08	1.76e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCND1—hematologic cancer	7.69e-08	1.75e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—JUN—hematologic cancer	7.67e-08	1.75e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK8—hematologic cancer	7.66e-08	1.75e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NCOR1—hematologic cancer	7.64e-08	1.74e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTM1—hematologic cancer	7.64e-08	1.74e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MDM2—hematologic cancer	7.63e-08	1.74e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CREBBP—hematologic cancer	7.63e-08	1.74e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EP300—hematologic cancer	7.63e-08	1.74e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—KRAS—hematologic cancer	7.62e-08	1.74e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—hematologic cancer	7.62e-08	1.74e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—hematologic cancer	7.6e-08	1.73e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK3—hematologic cancer	7.59e-08	1.73e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—hematologic cancer	7.57e-08	1.72e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—hematologic cancer	7.53e-08	1.72e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—hematologic cancer	7.52e-08	1.71e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HRAS—hematologic cancer	7.49e-08	1.71e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EP300—hematologic cancer	7.47e-08	1.7e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HRAS—hematologic cancer	7.45e-08	1.7e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1A—hematologic cancer	7.44e-08	1.7e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTEN—hematologic cancer	7.44e-08	1.69e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MTOR—hematologic cancer	7.43e-08	1.69e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CB—hematologic cancer	7.43e-08	1.69e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PTEN—hematologic cancer	7.42e-08	1.69e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SRC—hematologic cancer	7.42e-08	1.69e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—hematologic cancer	7.38e-08	1.68e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—hematologic cancer	7.36e-08	1.68e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PIK3CA—hematologic cancer	7.34e-08	1.67e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	7.31e-08	1.67e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—hematologic cancer	7.31e-08	1.66e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PIK3CA—hematologic cancer	7.27e-08	1.66e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK8—hematologic cancer	7.26e-08	1.65e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SRC—hematologic cancer	7.26e-08	1.65e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CD—hematologic cancer	7.24e-08	1.65e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MTHFR—hematologic cancer	7.23e-08	1.65e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—hematologic cancer	7.22e-08	1.65e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—KRAS—hematologic cancer	7.2e-08	1.64e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—hematologic cancer	7.17e-08	1.63e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—STAT3—hematologic cancer	7.15e-08	1.63e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—hematologic cancer	7.15e-08	1.63e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—hematologic cancer	7.14e-08	1.63e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NRAS—hematologic cancer	7.14e-08	1.63e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—hematologic cancer	7.13e-08	1.63e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—hematologic cancer	7.13e-08	1.62e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—hematologic cancer	7.1e-08	1.62e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—EP300—hematologic cancer	7.09e-08	1.62e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EP300—hematologic cancer	7.08e-08	1.61e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—hematologic cancer	7.07e-08	1.61e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—KRAS—hematologic cancer	7.04e-08	1.6e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—hematologic cancer	7.03e-08	1.6e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—PIK3CA—hematologic cancer	7e-08	1.6e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—STAT3—hematologic cancer	7e-08	1.6e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NRAS—hematologic cancer	6.99e-08	1.59e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—hematologic cancer	6.98e-08	1.59e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1B—hematologic cancer	6.97e-08	1.59e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CG—hematologic cancer	6.97e-08	1.59e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—hematologic cancer	6.95e-08	1.58e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SRC—hematologic cancer	6.88e-08	1.57e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3R1—hematologic cancer	6.83e-08	1.56e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK3—hematologic cancer	6.83e-08	1.56e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CASP3—hematologic cancer	6.83e-08	1.56e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—hematologic cancer	6.82e-08	1.55e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KRAS—hematologic cancer	6.82e-08	1.55e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MTHFR—hematologic cancer	6.81e-08	1.55e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HRAS—hematologic cancer	6.79e-08	1.55e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MTHFR—hematologic cancer	6.75e-08	1.54e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HRAS—hematologic cancer	6.72e-08	1.53e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—hematologic cancer	6.7e-08	1.53e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK3—hematologic cancer	6.69e-08	1.52e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCND1—hematologic cancer	6.65e-08	1.52e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—hematologic cancer	6.65e-08	1.51e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—STAT3—hematologic cancer	6.64e-08	1.51e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—JUN—hematologic cancer	6.64e-08	1.51e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—hematologic cancer	6.63e-08	1.51e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NRAS—hematologic cancer	6.62e-08	1.51e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—hematologic cancer	6.62e-08	1.51e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PIK3CA—hematologic cancer	6.62e-08	1.51e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—hematologic cancer	6.58e-08	1.5e-06	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—hematologic cancer	6.58e-08	1.5e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NQO1—hematologic cancer	6.57e-08	1.5e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CD44—hematologic cancer	6.57e-08	1.5e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—hematologic cancer	6.51e-08	1.48e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—hematologic cancer	6.5e-08	1.48e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—hematologic cancer	6.49e-08	1.48e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—HRAS—hematologic cancer	6.48e-08	1.48e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—PIK3CA—hematologic cancer	6.47e-08	1.47e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CREBBP—hematologic cancer	6.46e-08	1.47e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—hematologic cancer	6.44e-08	1.47e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1A—hematologic cancer	6.43e-08	1.47e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTEN—hematologic cancer	6.42e-08	1.46e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—hematologic cancer	6.4e-08	1.46e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK3—hematologic cancer	6.34e-08	1.45e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CB—hematologic cancer	6.31e-08	1.44e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK8—hematologic cancer	6.28e-08	1.43e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PIK3CA—hematologic cancer	6.26e-08	1.43e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYCS—hematologic cancer	6.22e-08	1.42e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—hematologic cancer	6.2e-08	1.41e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PIK3CA—hematologic cancer	6.18e-08	1.41e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	6.18e-08	1.41e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—hematologic cancer	6.17e-08	1.41e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—hematologic cancer	6.15e-08	1.4e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KRAS—hematologic cancer	6.14e-08	1.4e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CD—hematologic cancer	6.13e-08	1.4e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HRAS—hematologic cancer	6.12e-08	1.39e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EP300—hematologic cancer	6.12e-08	1.39e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CG—hematologic cancer	6.07e-08	1.38e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—hematologic cancer	6.06e-08	1.38e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—hematologic cancer	6.05e-08	1.38e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KRAS—hematologic cancer	6.01e-08	1.37e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—hematologic cancer	5.99e-08	1.37e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—HRAS—hematologic cancer	5.98e-08	1.36e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SRC—hematologic cancer	5.95e-08	1.36e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.95e-08	1.36e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—hematologic cancer	5.94e-08	1.35e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—hematologic cancer	5.86e-08	1.33e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—hematologic cancer	5.8e-08	1.32e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HRAS—hematologic cancer	5.79e-08	1.32e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3R1—hematologic cancer	5.79e-08	1.32e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STAT3—hematologic cancer	5.74e-08	1.31e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NRAS—hematologic cancer	5.73e-08	1.3e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—hematologic cancer	5.73e-08	1.3e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CG—hematologic cancer	5.72e-08	1.3e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—hematologic cancer	5.72e-08	1.3e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KRAS—hematologic cancer	5.7e-08	1.3e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CG—hematologic cancer	5.67e-08	1.29e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PIK3CA—hematologic cancer	5.64e-08	1.29e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CREBBP—hematologic cancer	5.63e-08	1.28e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—hematologic cancer	5.55e-08	1.26e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PIK3CA—hematologic cancer	5.52e-08	1.26e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK3—hematologic cancer	5.48e-08	1.25e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTP1—hematologic cancer	5.48e-08	1.25e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—hematologic cancer	5.46e-08	1.24e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTEN—hematologic cancer	5.45e-08	1.24e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—hematologic cancer	5.4e-08	1.23e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—hematologic cancer	5.34e-08	1.22e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CB—hematologic cancer	5.34e-08	1.22e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CD—hematologic cancer	5.34e-08	1.22e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—hematologic cancer	5.33e-08	1.22e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—hematologic cancer	5.32e-08	1.21e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CREBBP—hematologic cancer	5.3e-08	1.21e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—hematologic cancer	5.28e-08	1.2e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—hematologic cancer	5.27e-08	1.2e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CREBBP—hematologic cancer	5.26e-08	1.2e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3CA—hematologic cancer	5.25e-08	1.2e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CA—hematologic cancer	5.24e-08	1.19e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HRAS—hematologic cancer	5.22e-08	1.19e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—EP300—hematologic cancer	5.2e-08	1.18e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ABCB1—hematologic cancer	5.19e-08	1.18e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—hematologic cancer	5.12e-08	1.17e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HRAS—hematologic cancer	5.11e-08	1.16e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—hematologic cancer	5.07e-08	1.15e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—hematologic cancer	5.05e-08	1.15e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3R1—hematologic cancer	5.04e-08	1.15e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTM1—hematologic cancer	5.04e-08	1.15e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NCOR1—hematologic cancer	5.04e-08	1.15e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CD—hematologic cancer	5.03e-08	1.15e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—hematologic cancer	5e-08	1.14e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CD—hematologic cancer	4.99e-08	1.14e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—hematologic cancer	4.97e-08	1.13e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KRAS—hematologic cancer	4.93e-08	1.12e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—hematologic cancer	4.92e-08	1.12e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—hematologic cancer	4.89e-08	1.11e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HRAS—hematologic cancer	4.85e-08	1.1e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3R1—hematologic cancer	4.75e-08	1.08e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3R1—hematologic cancer	4.71e-08	1.07e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CB—hematologic cancer	4.65e-08	1.06e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—hematologic cancer	4.64e-08	1.06e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTEN—hematologic cancer	4.61e-08	1.05e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—hematologic cancer	4.61e-08	1.05e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CA—hematologic cancer	4.53e-08	1.03e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—hematologic cancer	4.51e-08	1.03e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MTHFR—hematologic cancer	4.45e-08	1.01e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—EP300—hematologic cancer	4.4e-08	1e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CB—hematologic cancer	4.38e-08	9.99e-07	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—hematologic cancer	4.38e-08	9.98e-07	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CB—hematologic cancer	4.35e-08	9.9e-07	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—hematologic cancer	4.29e-08	9.76e-07	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—hematologic cancer	4.28e-08	9.75e-07	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HRAS—hematologic cancer	4.19e-08	9.55e-07	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTEN—hematologic cancer	4.02e-08	9.16e-07	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—hematologic cancer	4.01e-08	9.14e-07	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CA—hematologic cancer	3.85e-08	8.76e-07	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—EP300—hematologic cancer	3.83e-08	8.74e-07	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTEN—hematologic cancer	3.79e-08	8.63e-07	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTEN—hematologic cancer	3.76e-08	8.56e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CG—hematologic cancer	3.74e-08	8.52e-07	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—hematologic cancer	3.7e-08	8.43e-07	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—EP300—hematologic cancer	3.61e-08	8.23e-07	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—EP300—hematologic cancer	3.58e-08	8.16e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CREBBP—hematologic cancer	3.47e-08	7.9e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CD—hematologic cancer	3.29e-08	7.49e-07	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CA—hematologic cancer	3.26e-08	7.42e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—hematologic cancer	3.25e-08	7.4e-07	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—hematologic cancer	3.14e-08	7.16e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3R1—hematologic cancer	3.11e-08	7.08e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CB—hematologic cancer	2.87e-08	6.53e-07	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CA—hematologic cancer	2.84e-08	6.46e-07	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CA—hematologic cancer	2.67e-08	6.09e-07	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—hematologic cancer	2.66e-08	6.06e-07	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CA—hematologic cancer	2.65e-08	6.04e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTEN—hematologic cancer	2.48e-08	5.64e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—EP300—hematologic cancer	2.36e-08	5.38e-07	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—hematologic cancer	2.32e-08	5.28e-07	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—hematologic cancer	2.18e-08	4.97e-07	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—hematologic cancer	2.16e-08	4.93e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.75e-08	3.98e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—hematologic cancer	1.43e-08	3.25e-07	CbGpPWpGaD
